Collegium Pharmaceutical, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing; quarterly figures are included where material. Amounts below are in U.S. dollars.
Business context
Collegium sells three opioid pain products in the United States: Xtampza ER and Nucynta ER/IR. The products are Schedule II controlled substances. Revenue is generated from product sales, primarily through wholesale distributors.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Net revenue | $276.9 million | $310.0 million |
| Gross profit / gross margin | $150.6 million / 54.4% | $179.8 million / 58.0% |
| Operating income | $17.6 million | $56.2 million |
| Net income | $71.5 million | $26.8 million |
| Net cash from operations | $103.6 million | $93.9 million |
| Cash used in investing | $1.9 million | $373.8 million |
| Cash used in financing | $89.3 million | Cash provided: $286.5 million |
- Revenue fell 10.7%. Xtampza ER contributed $103.7 million, down from $128.0 million; Nucynta products contributed $173.2 million, down from $182.0 million.
- Net income included a $74.9 million income tax benefit, principally from releasing valuation allowances on deferred tax assets. Pre-tax results were a $3.4 million loss in 2021 versus $27.6 million income in 2020.
- Adjusted EBITDA, a company-defined non-GAAP measure, was $118.3 million, down from $139.7 million. GAAP operating expenses were $133.0 million, including $4.6 million of restructuring costs and $2.9 million of litigation settlements.
- Year-end cash and cash equivalents were $186.4 million; current assets were $315.5 million and current liabilities $279.6 million. The filing says available cash and expected operating inflows should fund planned operating expenses, debt service, and capital needs for the foreseeable future.
- Debt included $112.5 million principal on secured term notes, of which $50.0 million was scheduled for repayment in 2022, and $143.75 million face value of 2.625% convertible notes due 2026. The company reported compliance with loan covenants at year-end. Term-note interest is variable-rate and secured by substantially all material domestic assets.
Material changes and unusual items
- Fourth-quarter net revenue was $27.4 million, including a $38.3 million revenue reduction related to product-return adjustments. The quarter had a $25.0 million net loss; management attributed the return uncertainty to major disruptions in wholesalers’ processing of returns.
- The company formally denied a significant portion of unprocessed return claims, received payment for only part of denied claims, and intends to pursue collection of the short-paid receivables. The ultimate resolution remains uncertain. The filing does not provide a clear standalone amount for the resulting receivable exposure.
- Operating cash flow increased by $9.6 million year over year. 2020 investing outflows were dominated by the Nucynta acquisition; 2021 financing outflows included $47.9 million of share repurchases and $50.0 million of term-note repayments.
- Collegium released most of its deferred-tax valuation allowance in 2021. It also adopted new convertible-debt accounting, reducing reported interest expense and affecting earnings per share.
- In August 2021, the company authorized a $100 million share-repurchase program. By year-end, it had repurchased 2.15 million shares for $42.9 million, with $57.1 million remaining under the program.
Outlook, risks, and contingencies
- The filing provides no specific revenue or earnings guidance. Management expects COVID-19-related disruption to continue affecting pain-patient office visits and potentially product demand, with timing uncertain.
- On February 14, 2022, after year-end, Collegium agreed to acquire BioDelivery Sciences International for $5.60 per share in cash, with closing expected late in the first quarter of 2022 subject to conditions. A $650 million secured term-loan commitment was arranged to fund part of the acquisition, refinance debt, and cover fees; financing remains conditional.
- Key business risks include opioid regulation and public scrutiny, reimbursement and pricing pressure, competition, patent litigation, customer concentration, and reliance on single active-ingredient suppliers and contract manufacturers. Three customers represented 95% of 2021 revenue (35%, 31%, and 29%).
- Opioid-related lawsuits and government investigations remain ongoing. A settlement framework covering 27 lawsuits called for payments not exceeding $2.75 million, subject to final agreement and approvals. The company also agreed to pay the Massachusetts Attorney General $185,000 to resolve that office’s investigation. Purdue patent litigation continued; the company said it could not estimate the likelihood or range of potential loss.
- Xtampza ER and Nucynta ER manufacturing transitions and supply continuity are important execution risks. The filing also identifies uncertain product-return estimates as a significant accounting judgment and a critical audit matter.
Important facts for investors to verify
- How much of the disputed return-related receivables will ultimately be collected, and whether further revenue adjustments will be needed.
- Whether revenue and margins stabilize after the 2021 decline, including the impact of COVID-19 and product-return experience.
- Completion, financing terms, integration costs, and expected savings from the BDSI acquisition; in particular, the new facility’s repayment schedule and effect on leverage.
- Progress and regulatory approval of the Nucynta ER manufacturing transfer, plus qualification of secondary API suppliers.
- Developments in Purdue patent cases, opioid litigation and investigations, and any related cash costs or restrictions.
- Ongoing concentration among the three major customers and the company’s ability to meet debt covenants and service its debt.